全文获取类型
收费全文 | 1894篇 |
免费 | 105篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 50篇 |
妇产科学 | 11篇 |
基础医学 | 111篇 |
口腔科学 | 48篇 |
临床医学 | 116篇 |
内科学 | 852篇 |
皮肤病学 | 14篇 |
神经病学 | 57篇 |
特种医学 | 62篇 |
外科学 | 308篇 |
综合类 | 14篇 |
一般理论 | 1篇 |
预防医学 | 60篇 |
眼科学 | 59篇 |
药学 | 149篇 |
中国医学 | 8篇 |
肿瘤学 | 72篇 |
出版年
2024年 | 1篇 |
2023年 | 14篇 |
2022年 | 24篇 |
2021年 | 80篇 |
2020年 | 53篇 |
2019年 | 78篇 |
2018年 | 67篇 |
2017年 | 52篇 |
2016年 | 61篇 |
2015年 | 58篇 |
2014年 | 78篇 |
2013年 | 102篇 |
2012年 | 135篇 |
2011年 | 151篇 |
2010年 | 84篇 |
2009年 | 93篇 |
2008年 | 98篇 |
2007年 | 127篇 |
2006年 | 108篇 |
2005年 | 104篇 |
2004年 | 98篇 |
2003年 | 71篇 |
2002年 | 53篇 |
2001年 | 33篇 |
2000年 | 49篇 |
1999年 | 26篇 |
1998年 | 14篇 |
1997年 | 8篇 |
1996年 | 7篇 |
1995年 | 6篇 |
1994年 | 2篇 |
1993年 | 4篇 |
1992年 | 12篇 |
1991年 | 13篇 |
1990年 | 5篇 |
1989年 | 6篇 |
1988年 | 12篇 |
1987年 | 6篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1981年 | 2篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1973年 | 1篇 |
1970年 | 1篇 |
1969年 | 2篇 |
1966年 | 1篇 |
1962年 | 1篇 |
排序方式: 共有2010条查询结果,搜索用时 15 毫秒
91.
Jaya Chandrasekhar Usman Baber Samantha Sartori Melissa Aquino Annapoorna S. Kini Sunil Rao William Weintraub Timothy D. Henry Serdar Farhan Birgit Vogel Sabato Sorrentino Zhen Ge Samir Kapadia Joseph B. Muhlestein Sandra Weiss Craig Strauss Catalin Toma Anthony DeFranco Roxana Mehran 《The Canadian journal of cardiology》2018,34(3):319-329
Background
Potent P2Y12 inhibitors might offer enhanced benefit against thrombotic events in complex percutaneous coronary intervention (PCI). We examined prasugrel use and outcomes according to PCI complexity, as well as analyzing treatment effects according to thienopyridine type.Methods
PROMETHEUS was a multicentre observational study that compared clopidogrel vs prasugrel in acute coronary syndrome patients who underwent PCI (n = 19,914). Complex PCI was defined as PCI of the left main, bifurcation lesion, moderate-severely calcified lesion, or total stent length ≥ 30 mm. Major adverse cardiac events (MACE) were a composite of death, myocardial infarction, stroke, or unplanned revascularization. Outcomes were adjusted using multivariable Cox regression for effect of PCI complexity and propensity-stratified analysis for effect of thienopyridine type.Results
The study cohort included 48.9% (n = 9735) complex and 51.1% (n = 10,179) noncomplex patients. Second generation drug-eluting stents were used in 70.1% complex and 66.2% noncomplex PCI patients (P < 0.0001). Complex PCI was associated with greater adjusted risk of 1-year MACE (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.20-1.39; P < 0.001). Prasugrel was prescribed in 20.7% of complex and 20.1% of noncomplex PCI patients (P = 0.30). Compared with clopidogrel, prasugrel significantly decreased adjusted risk for 1-year MACE in complex PCI (HR, 0.79; 95% CI, 0.68-0.92) but not noncomplex PCI (HR, 0.91; 95% CI, 0.77-1.08), albeit there was no evidence of interaction (P interaction = 0.281).Conclusions
Despite the use of contemporary techniques, acute coronary syndrome patients who undergo complex PCI had significantly higher rates of 1-year MACE. Adjusted magnitude of treatment effects with prasugrel vs clopidogrel were consistent in complex and noncomplex PCI without evidence of interaction. 相似文献92.
Kenichi Tsujita MD PhD Akiko Maehara MD Gary S. Mintz MD Hiroshi Doi MD PhD Takashi Kubo MD PhD Celia Castellanos MD Jian Liu MD Junqing Yang MD Carlos Oviedo MD Theresa Franklin-Bond MS PA Neil Dasgupta MA Sinan Biro BS Lokesh Dani BA George D. Dangas MD PhD Roxana Mehran MD Ajay J. Kirtane MD Alexandra J. Lansky MD Edward M. Kreps MD Michael B. Collins MD Gregg W. Stone MD Jeffrey W. Moses MD Martin B. Leon MD 《The American journal of cardiology》2008,102(12):1608-1613
93.
94.
95.
We investigated whether intestinal lipoprotein overproduction in a fructose-fed, insulin-resistant hamster model is prevented with insulin sensitization. Syrian Golden hamsters were fed either chow, 60% fructose for 5 wk, chow for 5 wk with the insulin sensitizer rosiglitazone added for the last 3 wk, or 60% fructose plus rosiglitazone. In vivo Triton studies showed a 2- to 3-fold increase in the large (Svedberg unit > 400) and smaller (Sf 100-400) triglyceride-rich lipoprotein particle apolipoprotein B48 (apoB48) but not triglyceride secretion with fructose feeding in the fasted state (P < 0.01) and partial normalization with rosiglitazone in fructose-fed hamsters. Ex vivo pulse-chase labeling of enterocytes confirmed the oversecretion of apoB48 lipoproteins with fructose feeding. Intestinal lipoprotein oversecretion was associated with increased expression of microsomal triglyceride transfer protein expression. With rosiglitazone treatment of fructose-fed hamsters, there was approximately 50% reduction in apoB48 secretion from primary cultured enterocytes and amelioration of the elevated microsomal triglyceride transfer protein mass and activity in fructose-fed hamsters. In contrast, in the postprandial state, the major differences between nutritional and drug intervention protocols were evident in triglyceride-rich lipoprotein triglyceride and not apoB48 secretion rates. The data suggest that intestinal lipoprotein overproduction can be ameliorated with the insulin sensitizer rosiglitazone. 相似文献
96.
Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery 总被引:2,自引:0,他引:2
Dangas G Ellis SG Shlofmitz R Katz S Fish D Martin S Mehran R Russell ME Stone GW;TAXUS-IV Investigators 《Journal of the American College of Cardiology》2005,45(8):1186-1192
OBJECTIVES: We sought to examine the efficacy of paclitaxel-eluting stent implantation in the left anterior descending coronary artery (LAD). BACKGROUND: Restenosis and recurrent cardiac events after percutaneous intervention are more common for lesions in the LAD than other native coronary arteries, and often necessitate bypass surgery. Drug-eluting stents may improve the long-term prognosis of this high-risk group. METHODS: In the TAXUS-IV trial, 1,314 patients with single de novo coronary lesions were assigned to implantation of the slow-release, polymer-based, paclitaxel-eluting TAXUS stent or an identical bare-metal stent; 536 (41%) randomized patients had LAD lesions. RESULTS: Baseline characteristics of patients with LAD lesions were well-matched between the randomized groups. Late lumen loss at nine months after paclitaxel-eluting and control stent implantation were 0.28 +/- 0.51 mm and 0.54 +/- 0.57 mm, respectively (p = 0.0004), and binary restenosis rates were 11.3% and 26.9%, respectively (p = 0.004). At one year, major adverse cardiac events (MACE) occurred in 13.5% of TAXUS-treated patients versus 21.2% treated with the control stent (p = 0.01). The need for bypass surgery at one year was reduced among patients randomized to the TAXUS stent (2.6% vs. 6.3%, p = 0.02). In the proximal LAD subgroup (n = 126), the one-year target vessel revascularization rate was 7.9% with the TAXUS stent and 18.6% with the bare-metal stent (p = 0.009). CONCLUSIONS: Compared to bare-metal stents, implantation of polymer-based, paclitaxel-eluting stents in LAD lesions is safe, and reduces angiographic restenosis and MACE one year. Notably, the need for bypass graft surgery due to restenosis is reduced after TAXUS stent implantation in LAD lesions. 相似文献
97.
98.
99.
Moussa I Ellis SG Jones M Kereiakes DJ McMartin D Rutherford B Mehran R Collins M Leon MB Popma JJ Russell ME Stone GW 《The American journal of cardiology》2005,96(9):1242-1247
Randomized clinical trials have shown that paclitaxel-eluting stents significantly reduce restenosis after percutaneous coronary intervention. The impact of lesion calcification on the efficacy of paclitaxel-eluting stents is unknown. In the TAXUS-IV trial, 1,314 patients who underwent percutaneous coronary intervention were randomly assigned to a bare-metal or paclitaxel-eluting stent. By core laboratory analysis, 247 lesions (19%) were moderately or severely calcified. At the 9-month angiographic follow-up examination, the paclitaxel-eluting stent had significantly reduced the amount of late loss compared with the control stent (0.26 +/- 0.56 vs 0.51 +/- 0.48 mm, p = 0.015) within the analysis segment in the calcific lesions. The analysis segment restenosis rate was similar in patients with calcified and noncalcified lesions after paclitaxel-eluting stent implantation (7.5% vs 8.0%, respectively; p = 1.0). The rate of ischemia-driven target lesion revascularization (TLR) at 1 year was reduced by 56% in patients with calcified lesions (11.9% vs 5.1%, p = 0.09) and by 75% in noncalcified lesions (15.7% vs 4.3%, p <0.0001). By interaction testing, the efficacy of the paclitaxel-eluting stent in reducing TLR at 1 year was similar in the calcified and noncalcified lesions (p = 0.30). Moreover, by multivariate analysis, implantation of the paclitaxel-eluting stent was a powerful independent predictor of freedom from TLR, with similar hazard ratios for efficacy in calcified and noncalcified lesions (0.30 and 0.26, respectively). In conclusion, implantation of paclitaxel-eluting stents in patients with de novo coronary lesions significantly reduced restenosis in patients with and without calcified lesions. 相似文献
100.
Roxana Mehran Michela Faggioni Jaya Chandrasekhar Dominick J. Angiolillo Barry Bertolet Robert Lee Jobe Bassam Al-Joundi Somjot Brar George Dangas Wayne Batchelor Anand Prasad Hitinder S. Gurm James Tumlin Gregg W. Stone 《JACC: Cardiovascular Interventions》2018,11(16):1601-1610